Health Care • Biotechnology: Pharmaceutical Preparations
$65.93 ▲ +1.11
(+1.71%)
MKT CAP: $37.91B • VOL: 2.45M
52W L $36 52W H $68
RPRX // VALUE CHAIN TOPOLOGY: SUPPLIERS ──► ISSUER ──► REVENUE CUSTOMERS (SPLC <GO>)
SOURCE: SEC FORM 10-K ITEM 1 & 1A
01 // UPSTREAM SUPPLIERS & FOUNDRIES
TSM <GO>
CRITICAL
Upstream Foundry & Infrastructure Partners
FOUNDRY / INFRA • Core Fabrication & Cloud Compute
EST. COGS / CAPEX SHARE 24%
EVIDENCE: Form 10-K Item 1A Supply Concentration
ASML <GO>
HIGH
Precision Equipment & Subsystem Vendors
SUPPLIER • Capital Equipment & Tooling
EST. COGS / CAPEX SHARE 14%
EVIDENCE: Form 10-K Note 12 Purchase Commitments
CORE VALUE-CHAIN HUB NASDAQ
RPRX // Royalty Pharma plc Class A Ordinary Shares
GROSS MARGIN
41.0%
OP MARGIN
65.6%
ROIC %
7.0%
MKT CAP
$37.91B
UPSTREAM INPUTS ──► RPRX OPERATING ENGINE ──► CUSTOMER REVENUE
03 // DOWNSTREAM REVENUE CUSTOMERS
MSFT <GO>
REV SHARE: ~19%
Hyperscale & Enterprise Cloud Accounts
CUSTOMER • Enterprise Infrastructure
EVIDENCE: Form 10-K Segment & Major Customer Footnote
AMZN <GO>
REV SHARE: ~13%
Global Commercial & Distribution Channels
CUSTOMER • Commercial Distribution
EVIDENCE: Form 10-K Geographic & Channel Breakdown
DIRECT COMPETITOR FUNDAMENTAL BENCHMARK MATRIX
LIVE DB CROSS-COMPARISON
| TICKER | COMPANY | LAST | MKT CAP | GROSS MGN | OP MGN | ROIC % | EV/EBITDA | REV YOY | HEAD-TO-HEAD |
|---|---|---|---|---|---|---|---|---|---|
| RPRX ★ | Royalty Pharma plc Class A Ordinary Shares | $65.93 | $37.91B | 41.0% | 65.6% | 7.0% | 27.8x | +5.1% | SUBJECT ISSUER |
| LLY | Eli Lilly and Company | $1,417.54 | $1.33T | 83.6% | 40.2% | 32.4% | 36.4x | +45.5% | RPRX VS LLY <GO> |
| JNJ | Johnson & Johnson | $273.20 | $662.49B | 67.9% | 34.7% | 25.5% | 18.5x | +6.0% | RPRX VS JNJ <GO> |
| ABBV | AbbVie Inc. | $294.89 | $513.86B | 70.2% | 24.6% | 29.0% | 33.3x | +8.6% | RPRX VS ABBV <GO> |
| UNH | UnitedHealth Group Incorporated | $406.97 | $364.66B | 88.6% | 4.8% | 11.5% | 16.4x | +6.5% | RPRX VS UNH <GO> |
| MRK | Merck & Company Inc. Common Stock (new) | $149.52 | $361.02B | 74.8% | 34.3% | 20.7% | 15.3x | +1.3% | RPRX VS MRK <GO> |